PRIME Project

PRIME’s results will provide a transformational diagnostic-therapeutic treatment for epilepsy and other neurological diseases

There remain urgent and unmet needs for the treatment of neurological diseases. Epilepsy is a serious, chronic brain disease characterized by recurrent seizures.

Epilepsy is one of the most common serious neurological condition, affecting about 1% of the population, i.e. about 60 million people globally (6 million in Europe).

The end result of PRIME is a software design tool for designing engineered cells that compute, diagnose, and produce therapeutic molecules capable of preventing seizures. The design tool is governed by Artificial Intelligence (AI) integrated with Molecular Communication simulations that utilize Biophysical and Statistical Mechanics modelling. This trans-disciplinary project aims to approach a serious neurological problem through a solution bringing together synthetic biology, computer science, communication engineering, nanomedicine, bioengineering and material science. This vision of implanting programmable synthetic cells that mimic electronic computing circuits is not limited to managing epileptic seizures but may extend to many other neurological diseases.

Our Objectives

To develop an autonomous implantable living cell system with engineered bio- computing logic gate that sense, compute, and actuate epileptic seizure suppression. These cells will be implanted into the brain and will co-exist with natural neural tissue.


Objective One

Developing molecular communication simulation and modeling design tool.


Objective Two

Engineering cells to sense, perform logic computing and release GDNF


Objective Three

Developing an encapsulated implantable device that integrates three-dimensional (3D) constructs of the cells from Objective 2 grown in hybrid biomaterial scaffolds


Objective Four

Experimental testing and validation of device in vivo

Learn more about our objectives

Visit our objectives page to read more details about each and how we will measure success.

Our Partners

Keep up to Date

Latest news & events